Introduction {#sec1}
============

Osteoarthritis (OA), the most common form of arthritis, can cause progressive loss of joint function \[[@B1]\]. The distinguishing feature of OA is progressive degradation of articular cartilage accompanied by subsequent joint space narrowing and osteophyte formation at the joint margin, which together lead to chronic joint pain, deformity, and restricted motion \[[@B2],[@B3]\]. OA is a combined result of environmental and genetic factors, which account for nearly 50% of the risk of OA development \[[@B4]\]. Prior genome-wide association studies have \[[@B5]\] suggested polymorphisms in some genes may affect OA pathogenesis. Recently, Gao et al. \[[@B8]\] have conducted a meta-analysis indicating that the *SMAD3* gene rs12901499 polymorphism increases the risk of OA among both Asians and Caucasians. Lv et al. \[[@B9]\] have also conducted a meta-analysis indicating that the *ADAM12* gene rs1871054 polymorphism increases knee OA risk in the Asian population, whereas other polymorphisms (rs3740199, rs1044122, or rs1278279) in ADAM12 are not associated with knee OA in any population. Pan et al. \[[@B10]\] have performed an updated meta-analysis suggesting that the C allele and CC genotype of the *GDF5* gene are protective against knee OA susceptibility across different populations. Moreover, single-nucleotide polymorphisms (SNPs) in candidates, such as growth differentiation factor 5 genes, \[[@B11]\] vitamin D receptor, and \[[@B12]\] estrogen receptor-α \[[@B13]\] have been reported to be associated with OA. All the abovementioned SNPs of different genes contribute differently to the risk of OA development through various mechanisms. We hypothesized that candidate gene studies might provide insight into OA development.

Calmodulin (CALM) regulates many Ca^2+^-dependent cellular events involving an interplay among various proteins \[[@B14]\]. Ca^2+^-CALM signaling plays a crucial role in cartilage phenotype maintenance and chondrogenesis. CALM probably has pivotal roles in articular cartilage by maintaining the cartilage phenotype in response to mechanical stimuli in mature chondrocytes \[[@B15],[@B16]\], regulating articular chondrogenesis \[[@B17]\], and modulating the adhesion of chondrocytes to extracellular matrix proteins during cartilage repair. Thus, CALM1 may be involved in OA pathogenesis.

To date, several studies \[[@B17]\] have explored the relationship between polymorphisms of the *CALM1* gene, which is located on chromosome 14q32.11, and OA susceptibility. The association between *CALM1* gene SNPs and OA susceptibility may provide new research directions for OA studies. However, the findings of previous studies are conflicting and inconclusive because of clinical heterogeneity, different ethnic populations, and small sample sizes. A single case--control study is underpowered and inconclusive, owing to limited sample sizes. Meta-analysis is used to combine findings based on individual research studies to yield robust conclusions, especially when results from single case--control studies are incomprehensive and conflicting. Thus, to precisely elucidate the genetic roles of *CALM1* gene polymorphisms in OA development, we performed a comprehensive systematic review and meta-analysis to clarify the association between these SNPs and OA risk.

Materials and methods {#sec2}
=====================

This meta-analysis was performed in compliance with PRISMA guideline \[[@B23]\] (not registered, Supplementary Table S1).

Search strategy {#sec2-1}
---------------

PubMed, Embase, Medline, Cochrane Library, and Google Scholar were systematically searched to identify epidemiological studies published through January 2018 and to retrieve the genetic association studies on OA. The terms 'Calmodulin', 'CALM1', 'SNP', 'polymorphism', 'variant', 'osteoarthritis', and 'OA' were used to find all publications reporting *CALM1* gene polymorphisms and OA risk. No language or other restrictions were placed on the search. Full text was obtained if the abstract was insufficient to allow us to include or exclude a study. Furthermore, the reference lists of all the related citations were examined to identify any initially omitted studies.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

The inclusion criteria were as follows: (1) case--control study on humans; (2) observational study addressing OA patients and controls; (3) study evaluating the association between *CALM1* gene polymorphisms and susceptibility to OA; and (4) study with sufficient genetic frequency for extraction. The exclusion criteria were as follows: (1) incomplete data; (2) review or case report; and (3) duplicate or overlapping publication. All questionable publications were discussed and addressed by consensus. Three reviewers independently screened the titles and abstracts. In cases of uncertainty regarding any of the above essential information, the full article was retrieved for further scrutiny, or the authors of the individual trials were contacted directly for further information when necessary.

Data extraction and quality assessment {#sec2-3}
--------------------------------------

From each eligible study, two reviewers (Y.H.Y and H.Z.Y) independently extracted the following data: first name of the first author, year of publication, country and ethnicity of study population, type of OA, source of controls (SOC), sample size, genotype method, names of gene polymorphisms, and genotype frequencies in cases and controls. The two reviewers (Y.H.Y and H.Z.Y) independently assessed the methodological quality of the included studies according to the Newcastle--Ottawa Scale (NOS) \[[@B24]\]. The NOS criteria were scored on the basis of three aspects: (1) subject selection, 0--4; (2) comparability of subject, 0--2; and (3) exposure, 0--3. The total NOS scores ranged from 0 (lowest) to 9 (highest). All disagreements were resolved through discussion by consensus or through consultation with the senior reviewer if necessary. Hardy--Weinberg equilibrium (HWE) in controls was tested with Pearson's χ^2^ test (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). Studies with scores ≥6 were considered high quality.

Statistical analysis {#sec2-4}
--------------------

Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the association between *CALM1* gene polymorphisms and OA susceptibility. Owing to a lack of original data for sex and age, crude ORs were calculated. Five genetic models were used: (1) allele model; (2) recessive model; (3) homozygous model; (4) heterozygous model; and (5) dominant model. *P* \< 0.05 was considered significant. Heterogeneity across studies was assessed by using the Q statistic with its *P*-value and *I*^2^ statistic \[[@B25],[@B26]\]. If *I*^2^\<50% and *P*\>0.10, a fixed effects model was used in the calculations \[[@B27]\]; otherwise, a random effects model was applied \[[@B28]\]. Subgroup analyses were carried out on the basis of ethnicity, type of OA, and genotype methods. Potential publication bias was assessed with Egger's and Begg's linear regression tests \[[@B29]\]. Sensitivity analysis was performed by omitting each study in turn to determine the effect on the heterogeneity test and evaluate the stability of the overall results. All statistical analyses were conducted in Stata 11.0 (Stata Corporation, College Station, TX, U.S.A.). The significant findings were evaluated by calculating the false-positive report probability (FPRP) \[[@B30]\]. An FPRP threshold of 0.2 and a prior probability of 0.25 were set to detect an OR for a correlation with the tested genotype. FPRP \<0.2 implied a significant relationship \[[@B31],[@B32]\].

Functional prediction {#sec2-5}
---------------------

Potential functions of SNPs were extracted from dbSNP (<https://www.ncbi.nlm.nih.gov/snp/>). We also used bioinformatics databases such as Promo (<http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3>) and the MirSNP database (<http://bioinfo.bjmu.edu.cn/mirsnp/search/>) to analyze transcription factor binding sites (TFBS).

Results {#sec3}
=======

Characteristics of the included studies {#sec3-1}
---------------------------------------

The online search yielded 103 citations, of which 28 duplicates were removed. Then 61 of the 75 remaining citations were excluded after reviewing of titles and abstracts. The remaining 14 citations were sent for full text review, which excluded four citations without detailed genotype data and four non-case--control studies. Finally, six studies (2752 cases and 3259 controls) involving six SNPs were included. The year of publication ranged from 2005 to 2017. The numbers of cases and controls ranged from 183 to 920 and from 193 to 1008, respectively. Two included citations \[[@B17],[@B21]\] studied the association between *CALM1* gene polymorphisms in an Asian population and four included citations \[[@B18],[@B22]\] studied Caucasian population. Five of included citations \[[@B17]\] studied the association between the rs12885713 polymorphism of the *CALM1* gene and risk of OA. Mishra et al. \[[@B19]\] and Mototani et al. \[[@B17]\] found that the TT genotype of the rs12885713 polymorphism increases the risk for OA, while Shi et al. \[[@B21]\], Poulou et al. \[[@B20]\], and Loughlim et al. \[[@B18]\] did not find a significant correlation between the rs12885713 polymorphism and OA risk. More characteristics of the included citations are shown in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. A flowchart of reviews, showing the detailed selection process, is illustrated in [Figure 1](#F1){ref-type="fig"}. The NOS scores ranged from six to seven stars, thus suggesting that the included studies were all of high methodological quality \[[@B33]\].

![Flowchart of the literature search and selection for the present study](bsr-38-bsr20181128-g1){#F1}

###### Characteristics of included studies

  Author                Year   Nationality   OA type   Sample size (Female/male)   Age (mean)       Study SNPs   Genotype method   NOS          HWE (*P*-value)                      
  --------------------- ------ ------------- --------- --------------------------- ---------------- ------------ ----------------- ------------ ----------------- --- --- ---------- -----------------
  Mishra \[[@B19]\]     2017   India         Knee      500 (295/205)               500 (276/224)    F: 55.67     F: 55.52          rs12885713   TaqMan            3   1   3          Y (0.13)
                                                                                   M: 56.15         M: 54.95     rs3814843         TaqMan       3                 1   3   Y (0.59)   
                                                                                                                 rs2300496         TaqMan       3                 1   3   Y (0.11)   
  Shi \[[@B21]\]        2008   China         Knee      183 (124/59)                210 (142/68)     58.6         57.7              rs12885713   PCR-RFLP          3   1   3          Y (0.73)
  Poulou \[[@B20]\]     2008   Greece        Knee      158 (138/20)                193 (137/56)     F: 68.1      F: 60.0           rs12885713   PCR-RFLP          3   1   3          Y (0.13)
                                                                                   M: 72.4          M: 70.2                        PCR-RFLP     3                 1   3              
  Valdes \[[@B22]\]     2007   U.K.          Knee      603 (305/298)               596 (296/300)    F: 73.5      F: 72.1           rs3213718    PCR-RFLP          3   1   3          Y (as reported)
                                                                                   M: 72.1          M: 71.8                        PCR-RFLP     3                 1   3              
  Loughlin \[[@B18]\]   2006   U.K.          Hip       920 (547/373)               752 (393/359)    64           69                rs12885713   PCR-RFLP          2   1   3          Y (0.28)
  Mototani \[[@B17]\]   2005   Japan         Hip       428 (404/24)                1008 (491/517)   53.7         46.7              rs12885713   TaqMan            3   0   3          Y (0.27)
                                                                                                                 rs2300496         TaqMan       3                 0   3   Y (0.30)   
                                                                                                                 rs2300500         TaqMan       3                 0   3   Y (0.27)   
                                                                                                                 rs3213718         TaqMan       3                 0   3   Y (0.20)   
                                                                                                                 rs3179089         TaqMan       3                 0   3   Y (0.07)   

I, Selection; II, Comparability; III, Exposure. NOS is available from <http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>

###### Genotype distributions of CALM1 polymorphisms in the included studies

  Author & year               SOC   Ethnicity   Allele   Case   Control                                   Association with OA                           
  --------------------------- ----- ----------- -------- ------ ----------------------------------------- --------------------- ----- ----- ----- ----- -------------------------------------
  **rs12885713 (promotor)**                                                                                                                             
  Mishra, 2017                NA    Caucasian   T        C      158                                       240                   102   142   233   125   T increased/allele model (in women)
  Shi, 2008                   HB    Asian                       9                                         57                    117   8     70    132   Unrelated
  Poulou, 2008                HB    Caucasian                   38                                        80                    36    37    103   46    Unrelated
  Loughlin, 2006              NA    Caucasian                   296                                       478                   146   245   381   126   Unrelated
  Mototani, 2005              HB    Asian                       46                                        128                   160   22    154   199   TT increased/recessive model
  **rs2300496 (intron)**                                                                                                                                
  Mishra, 2017                NA    Caucasian   C        A      132                                       221                   147   113   220   167   Unrelated
  Mototani, 2005              HB    Asian                       46                                        129                   159   23    155   197   CC increased/recessive model
  **rs3213718 (intron)**                                                                                                                                
  Valdes, 2007                                  T        C      T vs. C, OR & 95% CI, 0.87 (0.74, 1.03)                                                 Unrelated
  Mototani, 2005              HB    Asian                       65                                        163                   198   79    435   492   TT increased/recessive model
  **rs3814843 (3′-UTR)**                                                                                                                                
  Mishra, 2017                NA    Caucasian   G        T      0                                         56                    444   0     23    477   GG increased/recessive model
  **rs2300500 (intron)**                                                                                                                                
  Mototani, 2005              HB    Asian       G        C      47                                        128                   159   23    156   196   GG increased/recessive model
  **rs3179089 (3′-UTR)**                                                                                                                                
  Mototani, 2005              HB    Asian       G        C      45                                        131                   158   20    160   195   GG increased/recessive model

Abbreviations: HB, hospital-based; NA, not available; PB, population-based.

Association between rs12885713 polymorphism and OA susceptibility {#sec3-2}
-----------------------------------------------------------------

General analysis showed rs12885713 polymorphism of *CALM1* gene increased OA risk (OR & 95% CI: 1.11 \[1.02--1.22\] in T vs. C; 1.40 \[1.02--1.91\] in TT vs. CC, [Table 3](#T3){ref-type="table"} & [Figure 2](#F2){ref-type="fig"}). Stratification analysis by ethnicity showed that the rs12885713 polymorphism increased the risk of OA among Asians (OR & 95% CI: 1.24 \[1.03--1.51\] in T vs. C; OR & 95% CI: 2.21 \[1.39--3.50\] in TT vs. TC + CC; 2.05 \[1.06--3.97\] in TT vs. CC, [Table 3](#T3){ref-type="table"} and [Figure 3](#F3){ref-type="fig"}). Subgroup analysis by OA type revealed that the rs12885713 polymorphism increased the risk of knee OA (OR & 95% CI: 1.34 \[1.01, 1.80\] in TT vs. CC, [Table 3](#T3){ref-type="table"} and [Figure 4](#F4){ref-type="fig"}), but not hip OA.

![Forest plot showing OR for the associations between the rs12885713 polymorphism and OA risk (T vs. C)](bsr-38-bsr20181128-g2){#F2}

![Stratification analysis by ethnicity showing OR for the association between the rs12885713 polymorphism and OA risk (TT vs. CC)](bsr-38-bsr20181128-g3){#F3}

![Stratification analysis by type of OA showing OR for the association between the rs12885713 polymorphism and OA risk (TT vs. CC)](bsr-38-bsr20181128-g4){#F4}

###### Meta-analysis of the association between CALM1 polymorphisms and OA risk

  SNP          Comparison                      Category               Category    Studies   OR (95% CI)             *P*-value   *P* for heterogeneity
  ------------ ------------------------------- ---------------------- ----------- --------- ----------------------- ----------- -----------------------
  rs12885713   T vs. C                         Total (Fixed model)                5         **1.11 (1.02--1.22)**   0.022       0.221
               Allele model                    Ethnicity              Asian       2         **1.24 (1.03--1.51)**   0.024       0.140
                                                                      Caucasian   3         1.08 (0.97--1.19)       0.165       0.410
                                               OA type                Knee        3         1.13 (0.99--1.30)       0.079       0.735
                                                                      Hip         2         1.10 (0.97--1.23)       0.131       0.026
                                               Genotype method        TaqMan      2         **1.24 (1.08--1.43)**   0.002       0.286
                                                                      PCR-RFLP    3         1.03 (0.91--1.16)       0.665       0.792
               TT + TC vs. CC                  Total (Fixed model)                5         1.14 (0.99--1.32)       0.071       0.732
               Dominant model                  Ethnicity              Asian       2         1.13 (0.89--1.43)       0.324       0.327
                                                                      Caucasian   3         1.15 (0.96--1.38)       0.129       0.594
                                               OA type                Knee        3         1.15 (0.93--1.43)       0.201       0.470
                                                                      Hip         2         1.14 (0.93--1.38)       0.202       0.480
                                               Genotype method        TaqMan      2         **1.26 (1.03--1.56)**   0.028       0.793
                                                                      PCR-RFLP    3         1.04 (0.85--1.27)       0.699       0.895
               TT vs. TC + CC                  Total (Random model)               5         1.30 (0.96--1.76)       0.086       0.023
               Recessive model                 Ethnicity              Asian       5         **2.21 (1.39--3.50)**   0.001       0.234
                                                                      Caucasian   2         1.07 (0.91--1.25)       0.410       0.430
                                               OA type                Knee        3         1.20 (0.95--1.52)       0.120       0.902
                                                                      Hip         2         1.54 (0.60--3.93)       0.371       0.001
                                               Genotype method        TaqMan      2         1.67 (0.77--3.61)       0.192       0.010
                                                                      PCR-RFLP    3         1.03 (0.86--1.24)       0.742       0.514
               TT vs. CC                       Total (Random model)               5         **1.40 (1.02--1.91)**   0.037       0.078
               Homozygote model                Ethnicity              Asian       2         **2.05 (1.06--3.97)**   0.033       0.212
                                                                      Caucasian   3         1.18 (0.96--1.46)       0.120       0.480
                                               OA type                Knee        3         **1.34 (1.01--1.80)**   0.045       0.987
                                                                      Hip         2         1.60 (0.65--3.90)       0.305       0.004
                                               Genotype method        TaqMan      2         1.82 (0.97--3.40)       0.063       0.051
                                                                      PCR-RFLP    3         1.10 (0.85--1.42)       0.475       0.774
               TC vs. CC                       Total (Fixed model)                5         **1.08 (0.93--1.26)**   0.332       0.800
               Heterozygote model              Ethnicity              Asian       2         **0.99 (0.77--1.28)**   0.951       0.663
                                                                      Caucasian   3         1.13 (0.93--1.37)       0.206       0.672
                                               OA type                Knee        3         1.10 (0.88--1.38)       0.411       0.462
                                                                      Hip         2         1.06 (0.86--1.30)       0.572       0.827
                                               Genotype method        TaqMan      2         1.14 (0.91--1.43)       0.246       0.380
                                                                      PCR-RFLP    3         1.03 (0.83--1.27)       0.813       0.811
  rs2300496    C vs. A                         Total (Fixed model)                2         **1.23 (1.07--1.42)**   0.003       0.329
               Allele model                                                                                                     
               CC + CA vs. AA dominant model   Total (Fixed model)                2         1.21 (0.99--1.48)       0.059       0.955
               CC vs. CA + AA                  Total (Random model)               2         1.67 (0.85--3.27)       0.133       0.024
               Recessive model                                                                                                  
               CC vs. AA                       Total (Random model)               2         1.75 (0.95--3.21)       0.072       0.055
               Homozygote model                                                                                                 
               CA vs. CC                       Total (Fixed model)                2         1.09 (0.88--1.35)       0.432       0.641
               Heterozygote model                                                                                               
  rs3213718    T vs. C                         Total (Fixed model)                          1.09 (0.98-1.21)        0.105       0.153
               Allele model                                                                                                     

\*Bold values are statistically significant (*P*\<0.05).

Sensitivity analysis was used to determine the pooled ORs regarding the effects of this SNP on OA risk; the results indicated that our data were stable and credible. The results of false-positive test also proved our findings (Supplementary Table S2). Neither Egger's nor Begg's tests revealed obvious publication bias for the rs12885713 polymorphism ([Figure 5](#F5){ref-type="fig"}).

![Begg's tests between the rs12885713 polymorphism and OA (T vs. C)](bsr-38-bsr20181128-g5){#F5}

Association between rs2300496/rs3213718 polymorphisms and OA susceptibility {#sec3-3}
---------------------------------------------------------------------------

The results of pooled analysis on the association between *CALM1* gene rs2300496/ rs3213718 polymorphisms and OA risk are shown in [Table 3](#T3){ref-type="table"}. The C allele (OR & 95% CI: 1.23 \[1.07--1.42\] in C vs. A) for the rs2300496 polymorphism increased the risk of OA as verified by a false-positive test (Supplementary Table S2), whereas the association was not found under the other four genetic models. Thus, we hypothesized that the rs2300496 polymorphism of CALM1 gene may increase the risk of OA susceptibility.

Owing to the incomplete genotype distribution data reported by Valdes et al. \[[@B22]\], only an allele model was used for the rs3213718 polymorphism, which indicated no association. Stratification analysis was not performed, owing to data unavailability.

The rs3814843, rs2300500, and rs3179089 polymorphisms of the *CALM1* gene were investigated in only one study \[[@B17],[@B19]\], which reported significant associations ([Table 2](#T2){ref-type="table"}). Nevertheless, further replication studies are required to confirm the associations.

Functional predictions {#sec3-4}
----------------------

Rs12885713 was located in TFBS. As shown in [Figure 6](#F6){ref-type="fig"} for rs12885713, if nucleotide C was changed to T, four new TFBS of the VDR, Zic1, Zic3, and MYBAS appeared, thus indicating that polymorphisms of this site may change the transcriptional efficiency of *CALM1*.

![Changed TFBS of rs12885713](bsr-38-bsr20181128-g6){#F6}

Two SNPs (rs3814843 and rs3179089) in the 3′-UTR of CALM1 may affect binding to microRNA. According to the MirSNP database (<http://bioinfo.bjmu.edu.cn/mirsnp/search/>), the CALM1 gene binds has-miR-497-5p when the nucleotide changes from A to C (for rs3814843). Has-miR-497-5p is a negative regulator of SMAD3 gene expression \[[@B36]\], and SMAD3 represses MMP13 expression, thereby maintaining articular cartilage and preventing OA \[[@B37]\]. We hypothesized that the minor allele of rs3814843 conferred susceptibility to OA by binding to has-miR-497-5p. For rs3179089, allelic changes affect binding to microRNAs, but these microRNAs have not been reported in the literature (Supplementary Figure S1).

Discussion {#sec4}
==========

To our knowledge, this is the first meta-analysis to investigate the associations between 6 *CALM1* gene SNPs and OA risk. Although the definite pathogenesis of OA remains unclear, genetic factors are considered to be strong determinants. Ca^2+^-CALM signaling has a known role in cartilage phenotype maintenance and chondrogenesis, and microarray analysis \[[@B17]\] has shown that CALM1 expression is elevated in both hip and knee OAs. Many studies \[[@B17]\] have explored the association between *CALM1* gene SNPs and OA susceptibility. Mototani et al. \[[@B17]\] have found that the rs12885713 polymorphism in the core promoter region of CALM1 is associated with hip OA in a Japanese population and CALM1 expression is elevated in cultured chondrocytes and articular cartilage. Loughlin et al. \[[@B18]\] have suggested that the rs12885713 polymorphism is not a risk factor for OA in the U.K., a result confirmed by another Caucasian study from Greece \[[@B20]\]. A Chinese study \[[@B21]\] also did not find a significant association for this SNP, results similar to findings among Indians. However, Mishra et al. \[[@B19]\] have indicated that *CALM1* gene rs12885713 polymorphism increases the risk of OA in females. The findings are clearly conflicting between Asians and Caucasians, possibly for the following six reasons. First, the inclusion criteria differed among studies. For example, Mototani et al. \[[@B17]\] used clinical symptoms and radiological evidence of joints, whereas Loughlin et al. \[[@B18]\] enrolled OA cases who underwent elective hip joint replacement. Second, the allele frequencies of the rs12885713 polymorphism in the cases were diverse. Third, the clinical phenotypes of OA were different. Fourth, the affected joint sites differed. Fifth, the genetic background of OA may vary among races. Finally, the sample sizes may also account.

Owing to their limited sample sizes, previous single studies may have been underpowered and thus have presented conflicting findings, especially given the diverse inheritance of the heterogeneous and complex OA etiology, different ethnicities, clinical heterogeneity, and other causes. Therefore, we conducted this meta-analysis. Our data showed that *CALM1* gene rs12885713 polymorphism increases the risk of OA. Furthermore, stratification analyses by ethnicity and OA types indicated that this polymorphism increases the risk of OA among Asians and in the knee, respectively. There are several possible reasons for the different findings regarding the rs12885713 polymorphism between Caucasians and Asians. First, genetic heterogeneity for OA exists in different populations. Second, these discrepancies may be explained by clinical heterogeneity. Third, the sample sizes of the Asian populations were not large enough relative to Caucasian populations to support a clear conclusion. Additionally, the different OA types (knee and hip OA) and varying clinical parameters of different populations may also be potential reasons for the inconclusive findings. As for the conflicting findings according to the OA site, we believe that *CALM1* gene rs12885713 polymorphism may be a specific variant for knee OA but not hip OA. Furthermore, the different characteristics of the OA groups (such as age and sex) and disease severity may also be possible reasons for the discrepancies. Finally, the varying environmental factors may also have contributed, because the interaction between genetic factors and environmental factors can eventually lead to the development of OA. Functional predictions indicated that the rs12885713 polymorphism may change the transcriptional efficiency of the *CALM1* gene. Thus, we assumed that changes in the transcriptional function by rs12885713 polymorphism may eventually alter CALM1 protein translation, thereby increasing the risk of OA. In addition, we believe that the effect of the rs12885713 polymorphism may be subtle, because this SNPs may be in linkage disequilibrium with other variants affecting the risk of OA (Supplementary Figure S2). Thus, further studies investigating other SNPs are urgently needed. Our meta-analysis also showed that the *CALM1* gene rs2300496 polymorphism, but not the rs3213718 polymorphism, may increase the risk of OA. As for other SNPs of the *CALM1* gene, the rs3814843, rs2300500, and rs3179089 polymorphisms were significantly associated with OA risk, although further replication studies are needed to confirm whether these SNPs influence the genetic risk of OA.

Some limitations of this meta-analysis should be considered. First, owing to limited data, we were unable to conduct stratification analyses of other potential factors, such as age, sex, and OA onset age. Second, our results were based on unadjusted estimates of confounding factors, which might have affected the final results. Third, although funnel plots and Egger's tests revealed no publication bias, selection bias could not be fully avoided, because only studies published in English were searched. Fourth, we were unable to assess potential gene--gene or gene--environment interactions because of the lack of relevant data. Fifth, the conclusions of some stratification analyses of the rs12885713 polymorphism should be interpreted with caution, owing to limited sample sizes. Sixth, clinical cases should be investigated in further studies to support these analytical results. Seventh, we can only infer but cannot conclude that the *CALM1* gene rs12885713 polymorphism is a susceptibility locus for other types of OA, thus necessitating further investigation into more types of OA. Finally, five genetic models of inheritance were used; thus, type I error may have arisen through a lack of correction for multiple testing.

In conclusion, the present meta-analysis demonstrates that the rs12885713 and rs2300496 polymorphisms of the *CALM1* gene, but not the rs3213718 polymorphism, may increase the risk of OA. Owing to the study limitations, further well-designed prospective studies with large sample sizes should be performed to confirm these findings.
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